Precision Diagnostics Market Size worth USD 138.85 billion in 2028 | Exhibiting a CAGR of 12.6%
31 janv. 2022 05h55 HE
|
Fortune Business Insights
Pune, India, Jan. 31, 2022 (GLOBE NEWSWIRE) -- The global precision diagnostics market size was USD 54.05 billion in 2020. The market is expected to grow from USD 60.35 billion in 2021 to USD 138.85...
4D Path, University of Leeds Extend Contract to Collaboratively Validate New Technology to Help Doctors More Accurately Diagnose Breast Cancer
16 mars 2021 10h00 HE
|
4D Path
NEWTON, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- 4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, has extended its existing partnership with the...
Dr. Jennifer Levin Carter Joins Advisory Board of Novel Precision Oncology Platform Creator 4D Path
15 déc. 2020 10h00 HE
|
4D Path
NEWTON, Mass., Dec. 15, 2020 (GLOBE NEWSWIRE) -- 4D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, is pleased to announce that Jennifer Levin Carter,...
4D Path Announces Patented Precision Oncology Platform for Instant Biomarker Profiling and Stratification Just From H&E Biopsy or Resection Images
12 nov. 2020 10h00 HE
|
4D Path
NEWTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- 4D Path, a company conceived by an experienced team of scientists, clinicians and management from leading research institutions including MIT,...
[2020-2026] Precision Diagnostics Market Size, Share, Growth, Trends, Revenue, Value, Competitive Landscape, Forecast Report by Fortune Business Insights
30 sept. 2020 08h57 HE
|
Fortune Business Insights
Pune, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Developments in The Human Genome Project have given tailwinds to the growth witnessed in the global precision diagnostics market. Fortune Business Insights...
US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the US
29 nov. 2018 06h00 HE
|
Invivoscribe, Inc.
SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Invivoscribe is pleased to announce FDA approval of both the LeukoStrat CDx FLT3 Mutation Assay and the Astellas drug, XOSPATA (gilteritinib fumarate),...
Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for Quizartinib
27 nov. 2018 06h00 HE
|
Invivoscribe, Inc.
SAN DIEGO, Nov. 27, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submissions of the LeukoStrat® CDx FLT3 Mutation Assay to...
Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan
19 nov. 2018 08h00 HE
|
Invivoscribe, Inc.
SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submission of the LeukoStrat® CDx FLT3 Mutation Assay to...